A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Trial Profile

A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Burosumab (Primary)
  • Indications Nevus; Osteomalacia
  • Focus Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 06 Oct 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2019.
    • 24 Aug 2017 According to a Kyowa Hakko Kirin media release, data from this trial will be presented at the American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting.
    • 17 Oct 2016 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top